Glp-1 weight loss denied as non-formulary by Cigna?

Cigna's commercial coverage policy IP0206 targets liraglutide (Saxenda, generic), Wegovy, and Zepbound for chronic weight management and requires prior authorization. For adult initial therapy, the patient must have a BMI ≥ 30 kg/m² (obesity), or a BMI exceeding 30 or a comorbid condition, such as diabetes or hypertension, with a BMI over 27 ; recognized weight-related comorbidities include hypertension, Type 2 diabetes, dyslipidemia (high cholesterol), obstructive sleep apnea, or cardiovascular disease . Pediatric criteria require BMI ≥ 95th percentile for age and sex . Initial approval durations differ by product: approve for 4 months for Saxenda initial therapy , approve for 7 months of Wegovy initial therapy , and approve for 8 months of Zepbound initial therapy , with 1-year reauthorization contingent on continued therapy and demonstrated weight-loss response. For continuation, response to pharmacologic therapy should be assessed after 3 months on a therapeutic dose; if treatment has not resulted in ≥ 5% weight loss, longer-term efficacy will not likely be sufficient and a change is recommended; individuals with weight reduction ≥ 5% should continue with their current treatment . Additional MACE-reduction coverage exists for Wegovy in adults with established cardiovascular disease with overweight or obesity (e.g., prior MI, stroke, or symptomatic peripheral arterial disease), and Wegovy for MASH/NASH must be prescribed by or in consultation with a physician who specializes in the condition being treated ; Wegovy is not indicated in patients with cirrhotic (F4) MASH . Combined use with another GLP-1 or GLP-1/GIP agonist is not approved, and quantity limits restrict claims to one GLP-1 agonist at a time.

- For BMI/comorbidity denials: cite FDA labeling and AACE/Obesity Society guidelines supporting pharmacotherapy at BMI ≥ 30 or ≥ 27 with comorbidities; submit chart documentation of measured BMI and ICD-10-coded comorbidity (HTN, T2DM E11, OSA G47.33, dyslipidemia E78). - For lifestyle-modification denials: provide documented participation in a structured reduced-calorie diet, physical activity, and behavioral counseling, consistent with the policy's own framework that treatment is to address complications and diseases, not solely to reduce BMI, and the choice of pharmacotherapy is based on obesity-related comorbidities ; reference the STEP and SURMOUNT trial protocols which paired drug therapy with lifestyle intervention. - For inadequate-response denials at reauthorization: provide weighed clinic measurements showing ≥ 5% loss; note the policy itself acknowledges patients who achieve ≥ 15% weight loss (the average observed with Wegovy and Zepbound) achieve a response that predictably prevents or improves a wide range of complications — supported by STEP 1 (Wilding NEJM 2021) and SURMOUNT-1 (Jastreboff NEJM 2022). - For cardiovascular indication denials on Wegovy: cite the SELECT trial (Lincoff NEJM 2023) showing 20% MACE reduction; per policy, established cardiovascular disease with overweight or obesity is approvable with documentation of prior MI, stroke, or symptomatic PAD. - For OSA-related denials on Zepbound: cite SURMOUNT-OSA results referenced in the policy itself — in both trials, Zepbound was superior to placebo for the primary endpoint; in Trial 1, the change in AHI at Week 52 with Zepbound was superior to placebo (-25.3 events/hour vs. -5.3 events/hour) ; align with ATS 2018 OSA weight-management guideline recommending anti-obesity pharmacotherapy in BMI ≥ 27 patients. - For MASH/NASH denials on Wegovy: provide specialist (hepatology/GI) attestation and documentation of stage F2 or F3 fibrosis confirmed by liver biopsy within 3 years, vibration-controlled elastography (VCTE), or MRE ; cite ESSENCE trial results. - For "not medically necessary" denials: reference ADA Standards of Care 2024 and AACE 2023 endorsing GLP-1 RAs and GLP-1/GIP agonists for chronic weight management with cardiometabolic comorbidities, and the AHA 2021 Scientific Statement on obesity and CVD risk.

## Why Cigna Denies GLP-1 Weight-Loss Treatment as Non-Formulary

Cigna's formulary for weight-management drugs varies by plan design. Some Cigna plans exclude all weight-loss medications from coverage; others cover certain GLP-1 agents at a preferred tier while leaving others off-formulary. A non-formulary denial for a GLP-1 weight-loss agent typically means either (a) the specific brand prescribed is not on the plan's covered drug list, or (b) the plan has a coverage exclusion for weight-loss or obesity medications as a category. These two situations require different appeal strategies.

## Why This Denial Is Appealable

If the denial is tier-based (the drug exists in the plan but at a non-covered tier), a formulary exception request is the right path — and it can succeed if a formulary alternative is clinically inappropriate. If the denial is based on a categorical exclusion of weight-loss drugs, the appeal landscape is narrower but not closed: if the drug is being prescribed primarily for an FDA-approved indication other than weight loss (such as type 2 diabetes or cardiovascular risk reduction) and your plan covers that indication, a re-coding or indication-specific appeal may apply. Always confirm the exact basis of the denial before choosing your appeal path.

## Your Federal Appeal Rights

• Formulary exception (first step for tier denials): Your prescriber submits a formulary exception request demonstrating that formulary alternatives are clinically inappropriate. Cigna must respond within a defined timeframe.
• Internal appeal (ERISA §503 / ACA §2719): For both tier and exclusion denials, you may file a formal written internal appeal. The plan must conduct a clinical review and issue a written decision.
• External review (ACA §2719): After internal exhaustion, request independent external review. External reviewers can overturn formulary denials when the clinical record establishes medical necessity for the specific non-formulary agent. Standard review closes within 45 days; expedited within 72 hours.
• Plan document review: For categorical exclusions, review your Summary Plan Description carefully. If the exclusion is ambiguous or if the drug's primary indication is not weight loss, the exclusion may not apply as Cigna has stated.

## Documentation to Gather

• Formulary alternative trial records (for tier denials): Dates, prescriptions, and clinical outcomes or intolerances for each GLP-1 or weight-management agent on Cigna's formulary that your prescriber considered or tried.
• Clinical rationale for the specific non-formulary agent: A prescriber letter explaining why the formulary alternatives are not clinically equivalent or appropriate for this patient — referencing the FDA-approved prescribing information for the prescribed drug and any relevant differences in the approved indication, delivery mechanism, or patient profile.
• Primary indication documentation (for exclusion denials): If the drug was prescribed primarily for type 2 diabetes, cardiovascular risk reduction, or another non-weight-loss indication, provide the diagnosis records and prescriber statement supporting that indication.
• Relevant guideline reference: Ask your prescriber to reference the applicable professional society guideline (e.g., American Diabetes Association, Obesity Medicine Association) generically in the letter.

## Criteria-Mapping Structure

Obtain Cigna's formulary exception criteria and the specific non-formulary policy language from the denial notice or Cigna's online medical policy library. Then:

| Exception or Appeal Criterion | Supporting Evidence | |---|---| | Formulary alternative tried or contraindicated | [Prescription/chart records with dates and outcomes] | | Non-formulary drug clinically necessary | [Prescriber letter citing FDA label and guideline] | | Primary indication covered by plan (if applicable) | [Diagnosis documentation and prescriber attestation] |

If Cigna applies a categorical weight-loss exclusion, the appeal letter should clearly frame the request around the covered clinical indication — not around weight management as a standalone goal.